Abstract:Newly discovered N‐benzenesulfonamide derivatives, including 6 b, 6 c, and 6 d, demonstrate remarkable anticancer properties by forming hydrogen bonds with crucial protein residues. Alongside broad‐spectrum antimicrobial and antifungal activities, compound 6 f exhibits potent antioxidant abilities. Integration of pharmacokinetic analyses, molecular docking, and dynamics simulations highlights their therapeutic potential, offering a multifaceted approach against cancer, oxidative stress, and microbial diseases. This study presents the synthesis and characterization of a newer series of N‐(1‐(2‐(phenylamino) pyrimidin‐4‐yl)‐1H‐indazol‐5‐yl)benzenesulfonamide (6 a–6 n) and N‐(6‐ethoxy‐1‐(2‐(phenylamino) pyrimidin‐4‐yl)‐1H‐indazol‐5‐yl)benzenesulfonamide (7 a–7 c) derivatives through the reaction of N‐(1‐(2‐chloropyrimidin‐4‐yl)‐1H‐indazol‐5‐yl) benzenesulfonamide (4 a–i) and N‐(1‐(2‐chloropyrimidin‐4‐yl)‐6‐ethoxy‐1H‐indazol‐5‐yl) benzenesulfonamide (5 a–i) with various aniline derivatives in isopropanol. The compounds were thoroughly evaluated for their biological activities, encompassing antifungal, antibacterial, and anticancer assays, as well as antioxidant potential in DPPH and ABTS assays. Compound 7 b (IC50: 0.0125 MIC), 6 e (IC50: 0.0128 MIC), and 6 i (IC50: 0.0128 MIC) demonstrated exceptional antibacterial efficacy, while 6 d (IC50: 0.0124 MIC), 6 f (IC50: 0.0125 MIC) and 7 c (IC50: 0.0118 MIC), exhibited notable antifungal activity. Compounds 6 c (IC50: 13.31±0.32 μM, A459) & (IC50: 22.36±1.76 μM, MCF7) displayed significant anticancer activity comparable to established drugs. Moreover, 6 b (IC50: 11.22±0.16 μM, A459) & (IC50: 18.21±1.32 μM, MCF7) and 6 d (IC50: 11.23±0.17 μM, A459) & (IC50: 18.31±1.41 μM, MCF7) showed remarkable anticancer potency. Notably, compound N‐(1‐(2‐(methyl(phenyl)amino)pyrimidin‐4‐yl)‐1H‐indazol‐5‐yl)‐4‐nitrobenzenesulfonamide (IC50:0.1090 μmol/mL for DPPH and IC50: 0.1286 μmol/mL for ABTS) exhibited the most significant antioxidant activity. Computational docking studies revealed robust binding interactions with target enzymes (PDB ID: 4JT3 for anticancer, PDB ID: 1EA1 for antifungal, PDB ID: 1KZN for antibacterial, PDB ID: 3SRG for antioxidant), supported by molecular dynamics simulations indicating consistent stability of the most potent compound within the binding sites of the target proteins. These findings underscore the therapeutic potential of these derivatives, warranting further investigation for potential clinical applications.

Synthesis, structure of the N-(Alkyl/Arylsulfonyl) substituted 5-(Bromo/Iodo)-3-methylindazoles and bioactivity screening against some of the biochemical targets linked to type 2 diabetes mellitus

Synthesis, Characterizations, Anti-Diabetic and Molecular Modeling Approaches of Hybrid Indole-Oxadiazole Linked Thiazolidinone Derivatives

Synthesis, molecular docking, enzyme inhibition and antioxidant potential of new 1H-benzo[ d ]imidazole-5-carboxamide derivatives

Investigating the potential of 6-substituted 3-formyl chromone derivatives as anti-diabetic agents using in silico methods

Synthesis, Antiproliferative Evaluation, and Molecular Docking of Thieno[3,2-e]indazole Derivatives

Indolyl imine compounds as multi-target agents; synthesis, antidiabetic, anticholinesterase, antioxidant activities and molecular modeling

Synthesis, biological evaluation, and molecular modelling of novel quinoxaline-isoxazole hybrid as anti-hyperglycemic

Indenoquinoxaline-phenylacrylohydrazide hybrids as promising drug candidates for the treatment of type 2 diabetes: In vitro and in silico evaluation of enzyme inhibition and antioxidant activity

Fluorinated indeno-quinoxaline bearing thiazole moieties as hypoglycaemic agents targeting α-amylase, and α-glucosidase: synthesis, molecular docking, and ADMET studies

Design, synthesis, molecular dynamic simulation, DFT analysis, computational pharmacology and decoding the antidiabetic molecular mechanism of sulphonamide-thiazolidin-4-one hybrids

Synthesis, molecular modelling, and biological evaluation of novel quinoxaline derivatives for treating type II diabetes

"Synergistic Innovation: Crafting Indazole Derivatives for Advanced Anticancer, Antioxidant, and Antimicrobial Efficacy through Integrative Design and Holistic Evaluation"

Ultrasound-assisted synthesis of 4-thiazolidinone Schiff bases and their antioxidant, α-glucosidase, α-amylase inhibition, mode of inhibition and computational studies

Synthesis, molecular docking study, MD simulation, ADMET, and drug likeness of new thiazolo[3,2-a]pyridine-6,8-dicarbonitrile derivatives as potential anti-diabetic agents

Discovery of novel 6-(piperidin-1-ylsulfonyl)-2 H -chromenes targeting α-glucosidase, α-amylase, and PPAR-γ: Design, synthesis, virtual screening, and anti-diabetic activity for type 2 diabetes mellitus

Efficient Synthesis of Promising Antidiabetic Triazinoindole Analogues via Solvent-Free Method: Investigating the Reaction of 1,3-Diketones and 2,5-Dihydro-3H-[1,2,4]triazino[5,6-b]indole-3-thione

Synthesis, characterization and molecular modeling approach of hybrid pyrazole based thiazolidinone derivatives: An estimation and inhibition of diabetes mellitus

Synthesis, spectral analysis, DFT calculations, biological potential and molecular docking studies of indole appended pyrazolo-triazine

Developing Correlation Between In Silico Molecular Modeling and In Vitro α‐Amylase, Anti‐Cancer and SARS‐COV‐2 Studies of Bis‐Indole Derived Triazine‐Based Thiazolidinone Hybrid Derivatives

Preparation of Novel 3,4,5‐Triaryl‐1,2,4‐Oxadiazole Derivatives: Molecular Docking and α‐Glucosidase assessment

Novel 5-bromoindole-2-carboxylic Acid Derivatives as EGFR Inhibitors: Synthesis, Docking Study, and Structure Activity Relationship